CoChat

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Open access
VanderWalde, Ari, Bellasea, Shay L., Kendra, Kari L., Khushalani, Nikhil I., Campbell, Katie M., Scumpia, Philip O., Kuklinski, Lawrence F., Collichio, Frances, Sosman, Jeffrey A., Ikeguchi, Alexandra, Victor, Adrienne I., Truong, Thach-Giao, Chmielowski, Bartosz, Portnoy, David C., Chen, Yuanbin, Margolin, Kim, Bane, Charles, Dasanu, Constantin A., Johnson, Douglas B., Eroglu, Zeynep, Chandra, Sunandana, Medina, Egmidio, Gonzalez, Cynthia R., Baselga-Carretero, Ignacio, Vega-Crespo, Agustin, Garcilazo, Ivan Perez, Sharon, Elad, Hu-Lieskovan, Siwen, Patel, Sapna P., Grossmann, Kenneth F., Moon, James, Wu, Michael C., Ribas, Antoni · 2023 · Nature Medicine
Cited by 176

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free survival. Secondary endpoints included the difference in CD8 T cell infiltrate among responding and nonresponding tumors, objective response rate, overall survival and toxicity. The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio = 0.63, 90% confidence interval (CI) = 0.41–0.97, one-sided P = 0.04). Objective response rates were 28% (90% CI = 19–38%) and 9% (90% CI = 2–25%), respectively (one-sided P = 0.05). Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens. The change in intratumoral CD8 T cell density observed in the present analysis did not reach statistical significance to support the formal hypothesis tested as a secondary endpoint. In conclusion, primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade. Clinicaltrials.gov identifier: NCT03033576 . Patients with stage 4 or unresectable stage 3 melanoma refractory to first-line anti-programmed death protein 1 (PD-1) or anti-programmed cell death 1 ligand 1 have longer progression-free survival when treated with a combination of anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) and anti-PD-1 versus anti-CTLA-4 alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02498-y

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Metadata

Authors
VanderWalde, A., Bellasea, S. L., Kendra, K. L., Khushalani, N. I., Campbell, K. M., Scumpia, P. O., Kuklinski, L. F., Collichio, F., Sosman, J. A., Ikeguchi, A., Victor, A. I., Truong, T.-G., Chmielowski, B., Portnoy, D. C., Chen, Y., Margolin, K., Bane, C., Dasanu, C. A., Johnson, D. B., Eroglu, Z., Chandra, S., Medina, E., Gonzalez, C. R., Baselga-Carretero, I., Vega-Crespo, A., Garcilazo, I. P., Sharon, E., Hu-Lieskovan, S., Patel, S. P., Grossmann, K. F., Moon, J., Wu, M. C., & Ribas, A.
Venue
Nature Medicine
Published
2023-08-17
Volume
29
Issue
9
Pages
2278-2285
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4385955262
Cited by
176
References
16
FWCI
18.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02498-y
The paper
VanderWalde, A., Bellasea, S. L., Kendra, K. L., Khushalani, N. I., Campbell, K. M., Scumpia, P. O., Kuklinski, L. F., Collichio, F., Sosman, J. A., Ikeguchi, A., Victor, A. I., Truong, T.-G., Chmielowski, B., Portnoy, D. C., Chen, Y., Margolin, K., Bane, C., Dasanu, C. A., Johnson, D. B., . . . Ribas, A. (2023). Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02498-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.